Treatment options are limited for recurrent high-grade glioma, or HGG.
Current standard of care patients with newly diagnosed glioblastoma, or GBM, includes surgery, radiation therapy and chemotherapy. Approved drug treatments for HGG or GBM include:
- Temozolomide (Temodar). Temozolomide is FDA approved for the treatment of GBM, and AA. In patients with newly diagnosed GBM, temozolomide provided a median survival advantage of 2.5 months when added to surgery and radiation therapy. Source: Temodar prescribing information.
- Bevacizumab (Avastin). FDA granted accelerated approval to bevacizumab for the treatment of recurrent GBM. Thus far, no definitive data have demonstrated that bevacizumab improves disease-related symptoms or survival. Source: Avastin prescribing information.
- Lomustine (CCNU, Ceenu). Lomustine is an anti-cancer chemotherapy that is FDA approved to be used alone or with other drugs to treat recurrent brain cancer. Source: Ceenu prescribing information.
- Carmustine wafer (BCNU, Gliadel). Gliadel is an alkylating agent that is FDA approved for the treatment of newly diagnosed high-grade-malignant glioma (HGG) as an adjunct to surgery and radiation and recurrent GBM as an adjunct to surgery. In patients with newly diagnosed HGG, Gliadel showed a 2.3 month improvement in survival. Survival improvement was not statistically significant in the subgroup of patients with GBM. In recurrent high-grade glioma there was a median survival advantage of about 1.9 months. Survival prolongation was not observed in patients with pathologic diagnoses other than GBM. Source: Gliadel prescribing information.
Tocagen is developing an investigational therapy to treat recurrent HGG, which is under evaluation in an ongoing Phase 3 clinical trial, Toca 5. Learn about the Toca 5 trial.
See additional brain cancer resources below: